Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases

Novel Antioxidants Protect Mitochondria from the Effects of Oligomeric Amyloid Beta and Contribute to the Maintenance of Epigenome Function

“…32,33 These compounds have been shown to suppress ROS and lipid peroxidation and appear to function catalytically. 23,24 They also have been shown to maintain mitochondrial membrane potential in cultured FRDA lymphocytes under conditions of induced oxidative stress, and to confer strong cytoprotection to cultured lymphocytes derived from patients with a number of mitochondrial diseases. 24 Compound 1 was found to be unusual among MRQ analogues in that it also augments ATP production in coenzyme Q 10 -deficient human lymphocytes and FRDA lymphocytes.…”

“…23,24 They also have been shown to maintain mitochondrial membrane potential in cultured FRDA lymphocytes under conditions of induced oxidative stress, and to confer strong cytoprotection to cultured lymphocytes derived from patients with a number of mitochondrial diseases. 24 Compound 1 was found to be unusual among MRQ analogues in that it also augments ATP production in coenzyme Q 10 -deficient human lymphocytes and FRDA lymphocytes. 23,24 Because they function in part by quenching radicals involved in oxidative stress, the compounds have been denoted multifunctional radical quenchers (MRQs).…”

“…24 Compound 1 was found to be unusual among MRQ analogues in that it also augments ATP production in coenzyme Q 10 -deficient human lymphocytes and FRDA lymphocytes. 23,24 Because they function in part by quenching radicals involved in oxidative stress, the compounds have been denoted multifunctional radical quenchers (MRQs).…”

Иммунофармакологические Свойства Нового Производного 5-Оксипиримидина Снк-411

“…Ìíîãî÷èñëåííûå ñèíòåòè÷åñêèå ïðîèçâîäíûå ïè-ðèìèäèíîâ îáëàäàþò øèðîêèì ñïåêòðîì ôàðìàêîëî-ãè÷åñêîé àêòèâíîñòè è âîâëå÷åíû â ðåãóëÿöèþ èììóí-íîãî îòâåòà è ïðîöåññîâ ðåãåíåðàöèè [3,13,15]. Ëå-êàðñòâåííûå ïðîèçâîäíûå ïèðèìèäèíîâ ïðîÿâëÿþò êëèíè÷åñêóþ ýôôåêòèâíîñòü ïðè ëå÷åíèè îíêîëîãè÷å-ñêèõ, ïñèõîíåâðîëîãè÷åñêèõ çàáîëåâàíèé è òåðàïèè òðàâìàòè÷åñêèõ ñîñòîÿíèé [4,9].…”

“…Ëå-êàðñòâåííûå ïðîèçâîäíûå ïèðèìèäèíîâ ïðîÿâëÿþò êëèíè÷åñêóþ ýôôåêòèâíîñòü ïðè ëå÷åíèè îíêîëîãè÷å-ñêèõ, ïñèõîíåâðîëîãè÷åñêèõ çàáîëåâàíèé è òåðàïèè òðàâìàòè÷åñêèõ ñîñòîÿíèé [4,9]. Øèðîêèé ñïåêòð ôàðìàêîëîãè÷åñêîé àêòèâíîñòè è íèçêàÿ òîêñè÷íîñòü ñèíòåòè÷åñêèõ ïðîèçâîäíûõ ïèðèìèäèíîâ îïðåäåëÿ-þò àêòóàëüíîñòü ïîèñêà è ðàçðàáîòêè íîâûõ îðèãè-íàëüíûõ ëåêàðñòâåííûõ ñðåäñòâ â ðÿäó ïðîèçâîäíûõ ïèðèìèäèíîâ [5,9,10,13,15]. Ïîäîáíûé ñêðèíèíã â îòíîøåíèè 5-îêñèïèðèìèäèíîâ ïðîâîäèòñÿ ÔÃÁÍÓ "ÍÈÈ ôàðìàêîëîãèè èì.…”